A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

Item

http://www.wikidata.org/entity/Q24653999

Q24653999

about

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Afatinib in Non-Small Cell Lung Cancer Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer Preclinical Murine Models for Lung Cancer: Clinical Trial Applications Potential of afatinib in the treatment of patients with HER2-positive breast cancer The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors Strategies for modern biomarker and drug development in oncology.Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.Experimental approaches for the treatment of malignant gliomas.Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Loss of LKB1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts.Characteristics of CD8+ T cell subsets in Chinese patients with chronic HIV infection during initial ART.Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized c Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.Targeted therapies for non-small cell lung cancer: an evolving landscape.Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study.Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma.HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer.Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.

P2860

Q24594725-4055D533-01BD-4401-AB88-7E3BCC85BE43 Q24626194-CFB36024-7E53-4AEA-96FA-7052AD638202 Q24649935-17491172-9075-40FD-86F8-5E2BBC3A784F Q26749005-EEA5C609-2B6D-4E49-964C-EA93BA5F179B Q26824799-403B496E-EED9-4026-8EC7-1417CF59A1F5 Q26863474-1683AC1D-7528-4BA7-8CD7-58216FBB131F Q26999050-4ECD019C-D33A-4951-8B57-3DDE0FFD97B6 Q27021738-C6BE944C-3803-4EA2-9DE2-983151B57332 Q27851628-E80A5188-A798-446F-A50C-59EC741C105C Q27853013-580EC961-245A-4632-BC74-25409C1637B3 Q27853236-B9F99F05-3F17-408D-BA28-895C5ADC04D7 Q28075291-CCB6EDDF-E86C-49A0-B70C-B429733B371B Q28479059-2EF52639-8FDF-4381-8FE9-BBA12A901D00 Q28535038-362AEF6B-EE87-4E39-9332-621D6E2267FB Q30590270-16AF37C0-2FF6-4F01-A890-E499C841251A Q33839177-C419B05A-DB35-4D91-B3A4-896E8FC573EE Q33954583-57282FF1-CD3E-4EF3-A603-8E3A5092D401 Q34127138-B07D8791-D038-4E21-B090-275B5EA33574 Q34205052-679707B6-268C-490E-9575-A54AF3D8141D Q34260686-D4ED9572-391E-47C6-8B75-74C272BFD50C Q34497467-6AA8E568-7A36-4F7A-8DBE-8B366A89062A Q34602408-EFF86D74-DC0E-4C81-A34A-051A1FAF2489 Q34635475-3AC28979-2353-464E-BE29-46AB0A399F92 Q34740289-A1307A6A-B64E-45B3-B48D-AB691071A53C Q34778365-4AA6312C-29EC-4651-B89B-A6440FC56C43 Q34896542-98F03823-A7D8-4AB0-A341-F6C770A2F348 Q35043706-6444E817-C771-4905-A49C-10197E8E20D7 Q35628597-5BC5C634-1F32-4DA8-B354-9F0C893AAE77 Q35687574-3E692A29-483C-4444-AF3B-55F5F6039B5F Q35829430-C52BF182-4C85-444F-984D-242EBECE6796 Q35873072-4321CB24-E19B-4A65-AEF0-8F4CD8C0BF14 Q35896269-1A592398-F3AB-4814-B236-E6322E912BC5 Q35977527-42012D04-402A-435A-BAAE-F1DF6974804E Q36020920-456CD2DE-77FF-4DA5-81DC-FE58FD2364ED Q36071392-391DD7E5-CF55-4ED6-AFF1-5E04B185F6C7 Q36083906-0985DDF1-C3E9-4AEB-BC40-1F87A7615D3A Q36322762-A053D962-4FD7-48C7-8D11-3BD3F2D5C9F4 Q36402837-51904C19-C180-4918-8458-B03F83902F9B Q36406541-C4CC67B0-E61F-4B3C-A702-05761C0B278D Q36413392-398E8942-67BD-41B6-A4E8-5CABB49743AD

P2860

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

Item

http://www.wikidata.org/entity/Q24653999

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu